Ralston S H, Gallacher S J, Patel U, Dryburgh F J, Fraser W D, Cowan R A, Boyle I T
University Department of Medicine, Glasgow Royal Infirmary.
Lancet. 1989 Nov 18;2(8673):1180-2. doi: 10.1016/s0140-6736(89)91791-1.
Three intravenous bisphosphonates were compared in the treatment of cancer-associated hypercalcaemia. 48 patients were randomly allocated to one of three treatment groups (each with 16 subjects)--30 mg pamidronate or 600 mg clodronate, both as single intravenous infusions; or etidronate as three infusions of 7.5 mg/kg per day for three consecutive days. Patients were rehydrated with normal saline before bisphosphonate treatment. All three bisphosphonates lowered serum calcium by inhibiting bone resorption; pamidronate was the most potent in this respect. By comparison with the other groups, more patients in the pamidronate group became normocalcaemic, and the effect on serum calcium was apparent sooner and lasted longer.
比较了三种静脉注射双膦酸盐治疗癌症相关性高钙血症的效果。48例患者被随机分配到三个治疗组之一（每组16例）——30毫克帕米膦酸盐或600毫克氯膦酸盐，均单次静脉输注；或依替膦酸盐，连续三天每天静脉输注7.5毫克/千克，共三次。在双膦酸盐治疗前，患者用生理盐水进行补液。所有三种双膦酸盐均通过抑制骨吸收降低血清钙水平；在这方面，帕米膦酸盐最为有效。与其他组相比，帕米膦酸盐组中更多患者血钙恢复正常，且对血清钙的影响出现更早、持续时间更长。
